The Antifibrinolytic Not on the US Formulary: Reopening the Aprotinin Question
A 58-year-old woman facing a redo triple-valve repair carries the kind of bleeding risk aprotinin was once reserved for. The drug that might help her most isn't sold in this country anymore — and the argument for chasing it hinges on how much trust the room still puts in the trial that took it off the market.
Carmen V., a 58-year-old woman, had her mitral valve repaired twelve years ago and her aortic valve replaced with a bioprosthesis six years after that, and now returns with structural failure of both — a degenerated mitral repair with severe regurgitation and a stenotic bioprosthetic aortic valve, plus a tricuspid annulus dilated enough from years of right-heart strain to need its own repair. This will be a third sternotomy through what her surgeon described, reviewing her prior operative notes, as an unusually adherent mediastinum — dense enough that the team has already committed to peripheral cannulation before opening her chest, specifically to avoid catastrophic bleeding from an adherent structure during a blind sternal reentry.
This is, by any measure available to the team, close to the highest bleeding-risk category cardiac surgery produces: a third-time sternotomy, three valves addressed in one operation, and an anticipated bypass time long enough on its own to consume clotting factors regardless of what antifibrinolytic is running. Her renal function is normal and she carries no antiplatelet or anticoagulant therapy that would independently worsen the picture — this is bleeding risk driven entirely by surgical complexity, which is exactly the population aprotinin was reserved for before Bayer withdrew it worldwide in 2007 on the strength of BART's mortality signal. The awkward part is what happened next. The EMA re-reviewed that signal in 2012, concluded BART's results were unreliable, and lifted the suspension — but wrote the reinstated authorization narrowly, for isolated coronary artery bypass grafting in patients at high risk of major blood loss. Carmen is not an isolated CABG patient. The one regulator that looked again at this drug restored an indication her operation falls outside, which leaves her simultaneously the most compelling candidate for aprotinin on clinical grounds and outside the only modern authorization that exists for it.
Deciding the antifibrinolytic for the highest-risk field on the schedule
Tranexamic acid, high-dose protocol, and I don't think we should chase aprotinin for this case. It isn't FDA-approved or commercially available in the US — getting it here would mean an emergency-use import pathway, and that adds real delay to a case her surgeon has already flagged as possibly needing to move on short notice given her valve status.
I want to at least make the case before we close the door on it. Aprotinin is a broader serine protease inhibitor, genuinely more potent than TXA, and the mortality signal from BART that got it pulled has been questioned since — the EMA's own 2012 re-review concluded BART's results were unreliable and lifted the suspension, partly on the argument that surgeons were already preferentially reaching for aprotinin in sicker patients even inside the randomized design.
I take the delay concern seriously, but I don't think it's decisive on its own — her surgery isn't happening today, and if there's a realistic window to pursue special access before her scheduled date, I'd rather have made the attempt for a patient this high-risk than default to TXA purely because it's the familiar option.
You're right that the confounding-by-indication argument is real, and I'm not defending BART as beyond question — I'll concede the reanalysis point. But I want to be precise about what the EMA actually put back, because it cuts against using her as the example. The lifted authorization is narrow: isolated coronary artery bypass grafting, in patients at high risk of major blood loss, after the surgeon has weighed alternatives. It is not an authorization for on-pump cardiac surgery generally. Carmen is a third-time sternotomy having three valves addressed in one operation — she is not an isolated CABG patient, and the one regulator that took another look at this drug declined to put an operation like hers back inside its label. The thing that makes her the most compelling candidate on clinical grounds is exactly what puts her outside the only modern authorization that exists. Past that, we're a US center with no established aprotinin protocol, no staff experience dosing or monitoring it, and no confirmed timeline for special access before her date. I don't think "theoretically more potent, if we could get it" outweighs a drug our whole system already knows how to use safely at high dose.
If her surgeon can confirm a realistic access window with time to spare, I'm not opposed to revisiting this — but I don't think we should hold her surgery hostage to a pathway that may not come through, when TXA at maximal dose is a real, proven option sitting on the shelf today.
Agreed: high-dose TXA protocol, with peripheral cannulation planned before sternal reentry and fibrinogen concentrate staged for viscoelastic-guided administration post-bypass.
Not agreed as a settled principle: whether the confounding-by-indication reading of BART should change how the surgical group approaches aprotinin access requests going forward for similarly exceptional-risk cases, or whether today's decision was specific to this case's timeline rather than a broader practice shift. Both voices did accept the narrower factual point that emerged mid-discussion — that the EMA's reinstated indication covers isolated CABG only, so the strongest regulatory argument for aprotinin does not actually describe a redo triple-valve patient. The surgeon's request to explore a formal special-access relationship for future comparable cases was left open, not acted on today.